This HER2 status discrepancy between primary breast cancer and metastatic lymph node suggests that patients who have HER2-negative primary cancers but HER2-positive metastatic lymph nodes may miss the opportunity for successful treatment with tratsuzumab combination therapy. The gene discussed is ERBB2; the disease is breast carcinoma.